Aspirin and the risk of prostate cancer.
Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent. The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% CI) 0.81-1.50). No relation was found with duration of use (OR = 1.03 for <5 years, and 1.17 for > or =5 years) and time since first use (OR = 1.03 for <10 years, and 1.35 for > or =10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.
Bosetti
Cristina
C
Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy. bosetti@marionegri.it
Talamini
Renato
R
Negri
Eva
E
Franceschi
Silvia
S
Montella
Maurizio
M
La Vecchia
Carlo
C
D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D016022:Case-Control Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016017:Odds Ratio; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D012306:Risk
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D001241:Aspirin